ICH-E6-Annex1-ElectronicSystems-CSV-eSig-Audit-ALCOA-DataIntegrity | ICH E6(R3) Annex 1 - Computer Systems + Computer System Validation (CSV) + Electronic Signature + Audit Trail + ALCOA+ Data Integrity | 55 |
ICH-E6-Annex2-DecentralisedClinicalTrials-DCT-eConsent-Remote-Wearables | ICH E6(R3) Annex 2 - Decentralised Clinical Trial (DCT) Elements + eConsent + Remote Monitoring + Wearables + Real-World Evidence | 8 |
ICH-E6-DataMgmt-ExternalData-EHRs-RealWorldData-Coord-FDA-EMA | ICH E6 Data Management + External Data + EHR + Real-World Data + Coordination FDA + EMA + PMDA + ICH Family | 0 |
ICH-E6-EssentialDocs-TMF-eTMF-ArchiveRetention-ICH-Section8 | ICH E6 Section 8 - Essential Documents + Trial Master File (TMF) + eTMF + Archive + Retention | 9 |
ICH-E6-IRB-IEC-EthicsCommittee-InformedConsent-Vulnerable | ICH E6 Section 3 - Institutional Review Board (IRB) + Independent Ethics Committee (IEC) + Informed Consent + Vulnerable Populations | 1 |
ICH-E6-Investigator-Qualifications-Resources-Communication-SafetyReporting | ICH E6 Section 4 - Investigator + Qualifications + Resources + Communication + Safety Reporting + Source Document Verification | 1 |
ICH-E6-Protocol-IB-CSR-ClinicalStudyReport-Authoring | ICH E6 Section 6 + 7 - Protocol + Investigator Brochure (IB) + Clinical Study Report (CSR) + Reporting | 1 |
ICH-E6-Scope-Principles-R3-2025-Risk-Based-DecentralisedClinical | ICH E6 Good Clinical Practice - Scope + 13 Principles + R3 January 2025 + Risk-Based + Decentralised + Modernisation | 81 |
ICH-E6-Sponsor-QualityRiskMgmt-Monitoring-CRO-Vendor | ICH E6 Section 5 - Sponsor + Quality Management System + Risk-Based Monitoring + CRO + Vendor Oversight | 43 |
1.1-1.2 | IRB/IEC reviews the protocol, consent and assent materials, IB or product information, participant information, recruitment advertising, compensation plans, safety updates and inve | 0 |
1.3-1.5 | IRB/IEC has a qualified membership (recommended at least five, including a non-medical and an independent member) with only independent members voting, works to written procedures | 0 |
2.1-2.2 | Investigators are qualified by education, training and experience, know the investigational product, can show realistic recruitment potential and have enough time, staff and facili | 0 |
2.10-2.11 | Manage investigational product at the site (accountability, storage, use per protocol, participant instruction, direct-to-participant delivery safeguards) under investigator oversi | 0 |
2.12-records | Maintain and control the investigator's essential records per Appendix C, retain them for the required period or until the sponsor says they are no longer needed (whichever is long | 0 |
2.12-source | Ensure integrity of site data: ALCOA-quality source records with traceable changes, a defined source and capture plan, timely review of data including external data, correct use of | 0 |
2.12-systems | For site-deployed systems protect data from unauthorised access, alteration or loss, give secure attributable access, tell the sponsor of access changes for its systems, meet secti | 0 |
2.13 | On completion inform the institution, give the IRB/IEC a summary of the outcome and send regulators any required reports | 0 |
2.3 | Investigators delegate only to qualified, informed people and parties, keep a proportionate delegation record, document service provider agreements, retain responsibility and overs | 0 |
2.4 | Before starting, hold documented, dated IRB/IEC approval of the protocol, consent materials, recruitment procedures and participant information; supply the current IB, participant | 0 |
2.5 | Sign the protocol or agreement, comply with the protocol, GCP and regulation, document every deviation, explain and prevent recurrence of important ones, deviate only to remove imm | 0 |
2.6 | On premature termination or suspension, inform participants promptly and ensure appropriate therapy and follow-up, and notify the institution, sponsor, IRB/IEC and regulators as th | 0 |
2.7 | Keep a qualified physician or dentist responsible for trial medical care, provide adequate care for trial-related adverse events, inform the primary physician with consent, report | 0 |
2.8-content | Cover every applicable consent element (purpose, research nature, product and randomisation, procedures, expectations, risks including to partners and pregnancy, benefits or none, | 0 |
2.8-process | Run the consent process to regulation, GCP and Helsinki principles: approved materials, clear simple information, suitable media with a paper option, remote consent where appropria | 0 |
2.9 | When participation ends early or routinely, follow the protocol including steps to retain collected data, try respectfully to learn the reason for withdrawal without undue influenc | 0 |
3.1 | Design trials with enough supporting safety and efficacy data, quality built in around critical to quality factors, input from interested parties and operational feasibility withou | 0 |
3.10 | Run a proportionate, risk-based quality management system with quality by design, identifying, evaluating, controlling (including pre-specified acceptable ranges such as quality to | 0 |
3.11-QA | Maintain QA and QC processes and procedures; apply risk-based QA to find causes of serious noncompliance; and run independent, qualified, documented, risk-proportionate audits unde | 0 |
3.11-activities | Carry out monitoring activities across the life cycle (communication and deviation follow-up, site selection to close-out checks, investigational product checks and data checks) an | 0 |
3.11-monitoring | Apply risk-based QC to data handling and monitor by independent, qualified people using a risk-based mix of site (on-site or remote) and centralised monitoring set out in a tailore | 0 |
3.12 | Act proportionately on noncompliance, perform root cause analysis and CAPA for significant noncompliance, notify regulators and IRB/IEC of serious noncompliance, and consider endin | 0 |
3.13 | Evaluate product safety continuously: aggregate and review safety information promptly, communicate relevant new information, submit safety updates and periodic reports, expedite S | 0 |
3.14 | Provide insurance or indemnity where required, address treatment costs for trial-related injury, and compensate participants as regulation requires | 0 |
3.15-info-mfg | Develop and update the IB (or identify basic product information), characterise and manufacture investigational products to GMP with blinding-protective coding and compliant labels | 0 |
3.15-supply | Supply investigational product only after required approvals, with handling instructions, timely provision, records from shipment to disposition, retrieval and disposition processe | 0 |
3.16-data | Handle data with integrity and confidentiality: risk-focused QC, pre-specified data and collection methods, validated data tools, life-cycle processes, blinding safeguards and docu | 0 |
3.16-stats-records | Pre-specify analysis in a statistical analysis plan, control and trace programming and derivations, pre-define analysis set criteria, document and justify post-unblinding changes, | 0 |
3.16-systems | Keep a record of important computerised systems (use, functionality, interfaces, validation status, responsibility, access controls and security), implement section 4 requirements, | 0 |
3.17 | On termination or suspension inform investigators, regulators and the IRB/IEC promptly with reasons and give follow-up information; prepare clinical trial reports to ICH E3; and af | 0 |
3.2-3.5 | Provide sufficient resources, allocate roles before trial activities begin, use qualified individuals including readily available medical expertise, and document financing in an ag | 0 |
3.6 | Document agreements with investigators, institutions, service providers and committees before activities start, secure their commitments to GCP, recording, retention and access, do | 0 |
3.7-3.8 | Select qualified, adequately resourced investigators (and document coordinating roles), give them the protocol and current IB with time to review, make required regulatory submissi | 0 |
3.9 | Oversee the trial so design, conduct, processes and data give reliable results and protect participants: classify important protocol deviations, assess decisions for impact, tailor | 0 |
4-blinding | Address the key data governance processes (confidentiality, computerised systems, safeguarding randomisation, dosing and blinding, supporting key decisions) and protect blinding th | 0 |
4.2-capture-review | Cover the data life cycle with procedures: risk-based verification of transcribed data, metadata with all captured data, controlled automated validation checks, metadata and audit | 0 |
4.2-later | Correct errors in an attributed, justified, source-supported and timely way; transfer and migrate data through validated or reconciled processes; finalise data sets for analysis un | 0 |
4.3-operations | Release trial-specific systems to a site only after all its approvals, keep contingency procedures against data loss or inaccessibility, run help desk support with periodic review | 0 |
4.3-use-security | Define computerised system responsibilities, brief developers on purpose and requirements, involve intended users in design, document procedures for use, train users, and manage se | 0 |
4.3-validation | Own validation status across the life cycle with a risk-based approach that shows completeness, accuracy, reliability and consistent performance, validating before use, after risk- | 0 |
A | Ensure an up-to-date Investigator's Brochure (or justified product information alternative) with reference safety information, reviewed at least annually, presented objectively and | 0 |
B | Write protocols and amendments containing the required content: general and background information, objectives, design, participant selection, discontinuation and withdrawal, treat | 0 |
C | Manage essential records: identify which are essential by risk and relevance, keep them identifiable, version controlled and approved, hold them in TMF and ISF repositories with a | 0 |
P1 | Run trials ethically under Declaration of Helsinki principles, GCP and the law, with participants' rights, safety and well-being placed above science and society, timely safety rev | 0 |
P10 | Make roles and responsibilities clear and documented, keep overall responsibility when transferring or delegating activities, define them in agreements and oversee them | 0 |
P11 | Manufacture investigational products under applicable GMP, preserve their quality, use them per protocol, keep handling and labelling consistent with treatment assignment and blind | 0 |
P2 | Base participation on freely given, documented informed consent (or legally acceptable representative consent and minor assent) from a clear process suited to the trial, with defer | 0 |
P3 | Submit the trial to independent IRB/IEC review, conduct it under the approved protocol and undergo periodic IRB/IEC review | 0 |
P4 | Make trials scientifically sound, supported by adequate nonclinical and clinical data and current knowledge, and review new scientific information periodically for needed modificat | 0 |
P5 | Have trials designed and conducted by individuals qualified by education, training and experience for each task | 0 |
P6 | Build quality into trial design and conduct: treat quality as fitness for purpose, identify critical to quality factors prospectively, and prevent, detect and correct serious nonco | 0 |
P7 | Keep processes proportionate to risks to participants and the importance of the data, focus on risks beyond usual care, manage risks to critical factors proactively and avoid unnec | 0 |
P8 | Describe the trial in a clear, concise, scientifically sound and feasible protocol with explicit objectives and equally clear execution plans | 0 |
P9 | Generate reliable results through fit-for-purpose information, systems and validated computerised systems, robust record management, secure retention of essential records and trans | 0 |
intro | Purpose, scope and structure of ICH E6(R3) | 0 |